NCT04839315View on ClinicalTrials.gov

COVID-19 Vaccination in Rheumatic Disease Patients

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

February 9, 2022

Study Completion Date

February 9, 2022

Conditions
Systemic Lupus ErythematosusSjogren's SyndromeInflammatory MyositisPsoriatic ArthritisGoutAnkylosing SpondylitisArthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis)Osteoarthritis
Interventions
BIOLOGICAL

mRNA COVD19 vaccine

Subjects will receive two doses of mRNA based COVID19 vaccines.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04839315 - COVID-19 Vaccination in Rheumatic Disease Patients | Biotech Hunter | Biotech Hunter